Biotech firm Zymeworks' Q2 revenue jumps to $48.7 mln

Reuters

Aug 08

Biotech firm Zymeworks' <a href="https://laohu8.com/S/QTWO">Q2</a> revenue jumps to $48.7 mln

Overview

Zymeworks Q2 2025 revenue rises to $48.7 mln, driven by milestone payments
Net income for Q2 2025 reaches $2.3 mln, reversing last year's loss
FDA clears IND for ZW251, first-in-human studies planned for 2025

Outlook

Company expects cash resources to fund operations into 2H-2027

Result Drivers

MILESTONE PAYMENTS - $20 mln milestone from BeOne for zanidatamab approval in China and $7.5 mln from BMS commercial license option
PARTNERSHIP REVENUE - Revenue driven by strategic partnerships and collaborations, including Jazz and J&J

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Net Income		$2.32 mln
Q2 Income From Operations		-$674,000
Q2 Operating Expenses		$49.40 mln
Q2 Pretax Profit		$2.13 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Zymeworks Inc is $19.50, about 36.4% above its August 6 closing price of $12.41

Press Release: ID:nGNXtVNdB

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557594684"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557594684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557594684?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 05:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557594684","market":"nz","top_or_hot":-1,"title":"Biotech firm Zymeworks' Q2 revenue jumps to $48.7 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm Zymeworks' <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue jumps to $48.7 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Zymeworks Q2 2025 revenue rises to $48.7 mln, driven by milestone payments</p></li><li><p>Net income for Q2 2025 reaches $2.3 mln, reversing last year's loss</p></li><li><p>FDA clears IND for ZW251, first-in-human studies planned for 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash resources to fund operations into 2H-2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>MILESTONE PAYMENTS - $20 mln milestone from BeOne for zanidatamab approval in China and $7.5 mln from BMS commercial license option</p></li><li><p>PARTNERSHIP REVENUE - Revenue driven by strategic partnerships and collaborations, including Jazz and J&amp;J</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>$2.32 mln</p></td><td></td></tr><tr><td><p>Q2 Income From Operations</p></td><td></td><td><p>-$674,000</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$49.40 mln</p></td><td></td></tr><tr><td><p>Q2 Pretax Profit</p></td><td></td><td><p>$2.13 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Zymeworks Inc is $19.50, about 36.4% above its August 6 closing price of $12.41</p></li></ul><p>Press Release: <span>ID:nGNXtVNdB</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm Zymeworks' Q2 revenue jumps to $48.7 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm Zymeworks' Q2 revenue jumps to $48.7 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-08 05:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm Zymeworks' <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue jumps to $48.7 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Zymeworks Q2 2025 revenue rises to $48.7 mln, driven by milestone payments</p></li><li><p>Net income for Q2 2025 reaches $2.3 mln, reversing last year's loss</p></li><li><p>FDA clears IND for ZW251, first-in-human studies planned for 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash resources to fund operations into 2H-2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>MILESTONE PAYMENTS - $20 mln milestone from BeOne for zanidatamab approval in China and $7.5 mln from BMS commercial license option</p></li><li><p>PARTNERSHIP REVENUE - Revenue driven by strategic partnerships and collaborations, including Jazz and J&amp;J</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>$2.32 mln</p></td><td></td></tr><tr><td><p>Q2 Income From Operations</p></td><td></td><td><p>-$674,000</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$49.40 mln</p></td><td></td></tr><tr><td><p>Q2 Pretax Profit</p></td><td></td><td><p>$2.13 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Zymeworks Inc is $19.50, about 36.4% above its August 6 closing price of $12.41</p></li></ul><p>Press Release: <span>ID:nGNXtVNdB</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZYME","symbol_name":"ZYMEWORKS INC (US)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLX4A9D61:2","article_id":"2557594684","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557594684","pubTimestamp":1754601903,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biotech firm Zymeworks' Q2 revenue jumps to $48.7 mlnOverviewZymeworks Q2 2025 revenue rises to $48.7 mln, driven by milestone paymentsNet income for Q2 2025 reaches $2.3 mln, reversing last year's lo","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ZYME":"ZYMEWORKS INC (US)"},"translate_title":"生物技术公司Zymeworks第二季度收入跃升至4870万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZYME":0.9},"content_text":"Biotech firm Zymeworks' Q2 revenue jumps to $48.7 mlnOverviewZymeworks Q2 2025 revenue rises to $48.7 mln, driven by milestone paymentsNet income for Q2 2025 reaches $2.3 mln, reversing last year's lossFDA clears IND for ZW251, first-in-human studies planned for 2025OutlookCompany expects cash resources to fund operations into 2H-2027Result DriversMILESTONE PAYMENTS - $20 mln milestone from BeOne for zanidatamab approval in China and $7.5 mln from BMS commercial license optionPARTNERSHIP REVENUE - Revenue driven by strategic partnerships and collaborations, including Jazz and J&JKey DetailsMetricBeat/MissActualConsensus EstimateQ2 Net Income$2.32 mlnQ2 Income From Operations-$674,000Q2 Operating Expenses$49.40 mlnQ2 Pretax Profit$2.13 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Zymeworks Inc is $19.50, about 36.4% above its August 6 closing price of $12.41Press Release: ID:nGNXtVNdB(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}